Pneumococcal Pneumonia
11
1
1
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
36%
4 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (11)
Pneumococcal Community-Acquired Pneumonia Requiring Hospitalization Among Colombian Adults
Artificial Intelligence-driven Virtual Standardized Pediatric Patients Trial
Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
Pharmacist Impact on Pneumococcal Polysaccharide Vaccination Rates in Patients With Diabetes in a Supermarket Pharmacy Chain
The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
Phase I to Test a New Pneumococcal Vaccine
PCV10 Reactogenicity and Immunogenicity Study - Malindi
Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults
Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers
Study of Two Investigational Pneumococcal Vaccines in Healthy Adults
Targeting of Immune Response After Pneumococcal Vaccination